Pretraga

Rezultati

Risk for HER2 3+ breast cancer brain metastases significantly diminished five years after diagnosis [2011]

Tomašević, Zorica ; Milovanovic Z; Kovac Z; Tomasevic ZM; Inic M; Gavrilovic D

Relation of methylenetetrahydrofolate reductase C677T polymorphism to chronic myeloid leukemia in Serbia. [2011]

Janković, Radmila ; Jakovljevic, K.; Čavić, Milena ; Mališić, Emina

Revealing melanoma in situ on time using DELM, for the period of last five years in former Yugoslavia [2005]

Nikolić, Dejan; Nikolić, Aleksandra ; Stanimirović, Violeta; Granić, Miroslav ; Oprić, Miroslav

Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases [2024]

Mehta, Minesh P.; ...; Ilić, Rosanda ; ...; (broj koautora 18)

Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis. [2021]

Trukhin, Dmytro; Poddubskaya, Elena; Andric, Zoran G ; Bondarenko, Igor N; Shevnia, Serhii; Zaric, Bojan ; Bellala, Ravishankar; Charoentum, Chaiyut; Perez, Luis; Bullo, Felicitas;

Garcia, Fernanda;

Young patients with breast cancer: Comparison of molecular characteristics of pregnancy associated breast cancer with non-pregnancy associated breast cancer [2015]

Tomasevic, Zorica I ; Tomasevic, Zoran M ; Kovac, Zeljko; Milovanovic, Zorka M ; Minic, Ivana Z ; Milosevic, Snezana ; Bozovic-Spasojevic, Ivana M ; Zdrale, Zdravko; Markovic, Ivan Z ; Dzodic, Radan R

Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. [2010]

Ciuleanu, Tudor E; Samarzjia, M; Demidchik, Y; Beliakouski, V; Rancic, M; Bentsion, DL; Orlov, SV; Schaeffier, BA; De, Jager RL; Breitz, HB

Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial [2000]

Jeremic, B.; Shibamoto, Y.; Milicic, B.; Nikolic, N.; Dagovic, A. ; Aleksandrovic, J.; Vaskovic, Z.; Tadic, L.

Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364). [2025]

Kim, Sung Bae; ...; Kostic, Sanja; ...; (broj, koautora 20)

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer [2010]

du Bois, Andreas; Herrstedt, Jorn; Hardy-Bessard, Anne-Claire; Mueller, Hans-Helge; Harter, Philipp; Kristensen, Gunnar; Joly, Florence; Huober, Jens; Avall-Lundqvist, Elisabeth; Weber, Beatrice;

Kurzeder, Christian; Jelić, Svetislav; Pujade-Lauraine, Eric; Burges, Alexander; Pfisterer, Jacobus; Gropp, Martina; Staehle, Anne; Wimberger, Pauline; Jackisch, Christian; Sehouli, Jalid;